The belated long term review of one of the trials for Aducanumab DID achieve the primary end point. The major problem here is that the other trial didn't, and that's a consistency problem.
And there is no relationship to MSB's products or trials.
Alzheimer drug approved, page-62
-
- There are more pages in this discussion • 182 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.15 |
Change
0.000(0.00%) |
Mkt cap ! $1.304B | |||
| Open | High | Low | Value | Volume |
| $1.15 | $1.17 | $1.13 | $3.335M | 2.908M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 3905 | $1.21 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.10 | 141 | 1 |
View Market Depth
| Last trade - 15.59pm 22/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |